Douglas B. Evans
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Douglas B. Evans has a total of 153 co-authors. Here are the top co-authors by number of shared publications:
J L Abbruzzese
10 shared publicationsJeffrey E. Lee
From the Departments of Surgical Oncology, Gastrointestinal Medical Oncology, Radiation Oncology, Gynecologic Oncology, Pathology, and Diagnostic Imaging, The University of Texas M.D. Anderson Cancer Center, Houston, TX
9 shared publications- Christopher H. Crane
Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX
5 shared publications J E Lee
5 shared publicationsSuzanne E. Shapiro
Department of Surgical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Tex
5 shared publicationsK R Cleary
4 shared publications
Latest Publications
- 20 May 2010
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 28  (15) , e14514
Neoadjuvant versus upfront surgical strategies in patients with resectable pancreatic adenocarcinoma: A decision analysis.
E14514 Background: Postop chemotherapy ± radiation therapy (CRT) is standard for US patients (pts) with resected pancreatic cancer (PC). Neoadjuvant advantages include timely systemic treatment and optimal pt selection for surgery by excluding pts with rapidly progressive disease. Using a decision analysis model, benefits and risks of a neoadjuvant PC strategy were evaluated. Methods: We developed a Markov model to compare life expectancy (LE) in a simulated cohort of 10,000 resectable PC pts who were randomized to strategies of 1) attempted pancreatic resection, recovery and postop CRT; or 2) neoadjuvant CRT, restaging and surgery in the absence of progression. Probabilities were calculated using published data including median survival, assuming exponential survival decreases. Additional analyses used quality-adjusted life expectancy (QALE). Results: Neoadjuvant strategy offered a survival benefit over up-front surgical strategy (LE 20.1 vs. 18.9 mos). Sensitivity analyses were used to assess the importance of progression during preop CRT; when progression > 39.5%, upfront surgery became favored (in order to minimize Type I error, this analysis did not adjust for the fact that pts who progress on preop CRT would likely be early recurrences if randomized to upfront surgery). In an adapted model compensating for quality of life including surgery impact, neoadjuvant CRT proved increasingly superior to upfront surgery (QALE 19.8 vs. 16.4 mos). In a sensitivity analysis to test the potential effect of neoadjuvant regimens with different efficacy, neoadjuvant was favored provided that median survival > 21.5 mo after diagnosis among pts who received neoadjuvant + resection; the advantage of neoadjuvant improved as this median survival increased. Conclusions: Decision analysis modeling suggests that a neoadjuvant CRT strategy offers improved survival compared to a postoperative CRT strategy for resectable PC. Adjusting for quality of life increases the potential neoadjuvant advantage. Importantly, as survival duration increases, the neoadjuvant strategy is increasingly favored – suggesting an added value to neoadjuvant treatment as improved systemic therapies are developed. No significant financial relationships to disclose.
- 20 May 2010
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 28  (15) , e14514
Neoadjuvant versus upfront surgical strategies in patients with resectable pancreatic adenocarcinoma: A decision analysis.
E14514 Background: Postop chemotherapy ± radiation therapy (CRT) is standard for US patients (pts) with resected pancreatic cancer (PC). Neoadjuvant advantages include timely systemic treatment and optimal pt selection for surgery by excluding pts with rapidly progressive disease. Using a decision analysis model, benefits and risks of a neoadjuvant PC strategy were evaluated. Methods: We developed a Markov model to compare life expectancy (LE) in a simulated cohort of 10,000 resectable PC pts who were randomized to strategies of 1) attempted pancreatic resection, recovery and postop CRT; or 2) neoadjuvant CRT, restaging and surgery in the absence of progression. Probabilities were calculated using published data including median survival, assuming exponential survival decreases. Additional analyses used quality-adjusted life expectancy (QALE). Results: Neoadjuvant strategy offered a survival benefit over up-front surgical strategy (LE 20.1 vs. 18.9 mos). Sensitivity analyses were used to assess the importance of progression during preop CRT; when progression > 39.5%, upfront surgery became favored (in order to minimize Type I error, this analysis did not adjust for the fact that pts who progress on preop CRT would likely be early recurrences if randomized to upfront surgery). In an adapted model compensating for quality of life including surgery impact, neoadjuvant CRT proved increasingly superior to upfront surgery (QALE 19.8 vs. 16.4 mos). In a sensitivity analysis to test the potential effect of neoadjuvant regimens with different efficacy, neoadjuvant was favored provided that median survival > 21.5 mo after diagnosis among pts who received neoadjuvant + resection; the advantage of neoadjuvant improved as this median survival increased. Conclusions: Decision analysis modeling suggests that a neoadjuvant CRT strategy offers improved survival compared to a postoperative CRT strategy for resectable PC. Adjusting for quality of life increases the potential neoadjuvant advantage. Importantly, as survival duration increases, the neoadjuvant strategy is increasingly favored – suggesting an added value to neoadjuvant treatment as improved systemic therapies are developed. No significant financial relationships to disclose.
- 20 May 2010
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 28  (15) , 4113
Role of surveillance CT scans in resected PC: Correlation with CA19-9 and symptoms.
4113 Background: There is no data on the value of surveillance CT scans in pts with resected pancreatic adenocarcinoma (PC). In practice, onset of symptoms and/or abnormal blood tests including rising CA 19-9 often provides a leading indicator of disease recurrence. Methods: We performed a retrospective review to assess the value of surveillance CT scans (every 4-6 mo) compared to clinical symptoms and CA 19-9 levels. We collected data on pts with PC who underwent potentially curative surgery from Feb 1998 to Dec 2008. Results: 476 pts underwent 479 surgeries (Whipple= 417, Total = 9, Distal = 53). Of these, 308 (65%) recurred (299 definite, 9 suspicious), 15 (3%) were lost to follow-up and 156 (33%) were without recurrence and alive at last follow-up (117, 25%) or died of other causes (39). Site of first recurrence was distant and/or regional in 269 (87%) and isolated local recurrence in 35 (11%). Ca19-9 and symptoms data on 296 pts is available. 161 pts were symptomatic, 147 in the 3 mo preceding their CT. In 65, symptoms were clearly related to their cancer recurrence and in 82, correlation was not definite; residual effects from surgery or adjuvant therapy may have contributed. Correlation between CA19-9, symptoms and survival in pts that recurred is shown in the Table. In 40 (15%), cancer recurrence was noted only on body CT scan in the absence of symptoms and/or elevation of CA19-9. In 37, CT scan showed distant and/or regional recurrence, and only 3 pts showed isolated local recurrence. CA 19-9 and symptoms appear to be additive prognostic factors - asymptomatic pts with a normal CA 19-9 had a MS of 18 mo (from recurrence) compared to 10mo for those with either CA 19-9 elevation or symptoms and 5 mo when both were observed (p<0.0001). Conclusions: These data suggest that in the majority of pts with resected PC, symptoms and/or CA19-9 elevation precedes or accompanies disease recurrence (85%). Additional analyses evaluating pt variables including neoadjuvant therapy, pathology, PS and response to treatment are underway. Median overall survival (OS) in months from time of recurrence (FR) and from time of surgery (FS) Symptoms+ Symptoms− Total No. Pts OS FR OS FS No. Pts OS FR OS FS Elevated CA 19.9 115 5 17 95 10 23 210 Normal CA 19.9 46 10 23 40 18 35 86 Total 161 135 296 No significant financial relationships to disclose.
- 20 May 2010
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 28  (15) , 4113
Role of surveillance CT scans in resected PC: Correlation with CA19-9 and symptoms.
4113 Background: There is no data on the value of surveillance CT scans in pts with resected pancreatic adenocarcinoma (PC). In practice, onset of symptoms and/or abnormal blood tests including rising CA 19-9 often provides a leading indicator of disease recurrence. Methods: We performed a retrospective review to assess the value of surveillance CT scans (every 4-6 mo) compared to clinical symptoms and CA 19-9 levels. We collected data on pts with PC who underwent potentially curative surgery from Feb 1998 to Dec 2008. Results: 476 pts underwent 479 surgeries (Whipple= 417, Total = 9, Distal = 53). Of these, 308 (65%) recurred (299 definite, 9 suspicious), 15 (3%) were lost to follow-up and 156 (33%) were without recurrence and alive at last follow-up (117, 25%) or died of other causes (39). Site of first recurrence was distant and/or regional in 269 (87%) and isolated local recurrence in 35 (11%). Ca19-9 and symptoms data on 296 pts is available. 161 pts were symptomatic, 147 in the 3 mo preceding their CT. In 65, symptoms were clearly related to their cancer recurrence and in 82, correlation was not definite; residual effects from surgery or adjuvant therapy may have contributed. Correlation between CA19-9, symptoms and survival in pts that recurred is shown in the Table. In 40 (15%), cancer recurrence was noted only on body CT scan in the absence of symptoms and/or elevation of CA19-9. In 37, CT scan showed distant and/or regional recurrence, and only 3 pts showed isolated local recurrence. CA 19-9 and symptoms appear to be additive prognostic factors - asymptomatic pts with a normal CA 19-9 had a MS of 18 mo (from recurrence) compared to 10mo for those with either CA 19-9 elevation or symptoms and 5 mo when both were observed (p<0.0001). Conclusions: These data suggest that in the majority of pts with resected PC, symptoms and/or CA19-9 elevation precedes or accompanies disease recurrence (85%). Additional analyses evaluating pt variables including neoadjuvant therapy, pathology, PS and response to treatment are underway. Median overall survival (OS) in months from time of recurrence (FR) and from time of surgery (FS) Symptoms+ Symptoms− Total No. Pts OS FR OS FS No. Pts OS FR OS FS Elevated CA 19.9 115 5 17 95 10 23 210 Normal CA 19.9 46 10 23 40 18 35 86 Total 161 135 296 No significant financial relationships to disclose.
- Top Cited Papers
- 20 July 2008
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 26  (21) , 3496-3502
Preoperative Gemcitabine-Based Chemoradiation for Patients With Resectable Adenocarcinoma of the Pancreatic Head
Purpose: We conducted a phase II trial to assess the outcomes of patients who received preoperative gemcitabine-based chemoradiation and pancreaticoduodenectomy (PD) for stage I/II pancreatic adenocarcinoma. Patients and Methods: Eligible patients with pancreatic head/uncinate process adenocarcinoma and radiographically defined potentially resectable disease received chemoradiation with 7 weekly intravenous (IV) infusions of gemcitabine (400 mg/m2 IV over 30 minutes) plus radiation therapy (30 Gy in 10 fractions over 2 weeks). Patients underwent restaging 4 to 6 weeks after completion of chemoradiation and, in the absence of disease progression, were taken to surgery. Results: The study enrolled 86 patients. At the time of restaging, disease progression or a decline in performance status precluded 13 patients from surgery. Seventy-three (85%) of 86 patients were taken to surgery, extrapancreatic disease was found in nine, and 64 (74%) of 86 underwent a successful PD. Median overall survival (86 patients) was 22.7 months with a 27% 5-year survival. Median survival was 34 months for the 64 patients who underwent PD and 7 months for the 22 unresected patients (P < .001). The 5-year survival for those who did and did not undergo PD was 36% and 0%, respectively. Conclusion: Preoperative gemcitabine-based chemoradiation followed by restaging and evaluation for surgery separated the study population into two different subsets: patients likely to benefit from PD (n = 64) and those in whom surgery would be unlikely to provide clinical benefit (n = 22). Furthermore, the encouraging overall survival observed in this large trial supports the continued investigation of gemcitabine-based preoperative therapy in resectable pancreatic cancer.
- 20 July 2008
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 26  (21) , 3496-3502
Top Cited PapersPreoperative Gemcitabine-Based Chemoradiation for Patients With Resectable Adenocarcinoma of the Pancreatic Head
Purpose: We conducted a phase II trial to assess the outcomes of patients who received preoperative gemcitabine-based chemoradiation and pancreaticoduodenectomy (PD) for stage I/II pancreatic adenocarcinoma. Patients and Methods: Eligible patients with pancreatic head/uncinate process adenocarcinoma and radiographically defined potentially resectable disease received chemoradiation with 7 weekly intravenous (IV) infusions of gemcitabine (400 mg/m2 IV over 30 minutes) plus radiation therapy (30 Gy in 10 fractions over 2 weeks). Patients underwent restaging 4 to 6 weeks after completion of chemoradiation and, in the absence of disease progression, were taken to surgery. Results: The study enrolled 86 patients. At the time of restaging, disease progression or a decline in performance status precluded 13 patients from surgery. Seventy-three (85%) of 86 patients were taken to surgery, extrapancreatic disease was found in nine, and 64 (74%) of 86 underwent a successful PD. Median overall survival (86 patients) was 22.7 months with a 27% 5-year survival. Median survival was 34 months for the 64 patients who underwent PD and 7 months for the 22 unresected patients (P < .001). The 5-year survival for those who did and did not undergo PD was 36% and 0%, respectively. Conclusion: Preoperative gemcitabine-based chemoradiation followed by restaging and evaluation for surgery separated the study population into two different subsets: patients likely to benefit from PD (n = 64) and those in whom surgery would be unlikely to provide clinical benefit (n = 22). Furthermore, the encouraging overall survival observed in this large trial supports the continued investigation of gemcitabine-based preoperative therapy in resectable pancreatic cancer.
- Open Access
- 11 June 2008
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 15  (8) , 2078-2080
The Added Value of Multidisciplinary Care for Patients with Pancreatic Cancer
- 11 June 2008
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 15  (8) , 2078-2080
Open AccessThe Added Value of Multidisciplinary Care for Patients with Pancreatic Cancer
- 20 May 2008
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 26  (15_suppl) , 4630
Preoperative gemcitabine (gem) and bevacizumab (bev)-based chemoradiation for resectable pancreatic adenocarcinoma
4630 Background: Over 80% of pts who undergo potentially curative pancreaticoduodenectomy (PD) for pancreatic adenocarcinoma (PC) develop local or distant recurrence. Preoperative therapy maximizes the no. of pts who receive multimodality therapy and undergo a complete (R0) resection. Our phase I study using bev and capecitabine based chemoradiation for locally advanced PC was well tolerated. We hypothesized that gem and bev with RT in pts with resectable PC may allow more pts to undergo PD and improve the rate of R0 resections. Methods: Pts with biopsy proven, stage I/II adenoca of the pancreatic head or uncinate process received 6 wkly infusions of gem (400 mg/m2) and 3 infusions of bev (10 mg/kg, every 2 wks) with concomitant RT, 50.4 Gy at 1.8 Gy/fr. Pts were restaged 4–6 wks after the last dose of radiation. Those without disease progression and with good PS underwent surgery. Pts with adequate recuperation received bev (10mg/kg) every 2 weeks for 3 months starting ∼ 6 wks after surgery. Results: This study has enrolled 11 pts. Median age is 64 yrs; all pts had ECOG-PS 0–1. Median CA19–9 was 52. Of the 11 pts who finished chemoradiation, 10 underwent restaging and 1 pt died from cardiac arrest before restaging. At restaging, 1 pt. had metastatic disease, and 9 (90 %) went to surgery and underwent a successful (R0) PD. Pathologic PR rate (>50 % tumor kill) was 56 %. Preoperative grade 3–4 toxicities were infrequent and included stent related cholangitis (1), gastrointestinal toxicity (1), neutropenia (4), hypertension (1), and PE (1). Major postop complications occurred in 5 of the 9 pts (56%) who underwent PD including wound dehiscence (3) requiring reoperation, large ventral hernia related to fascial dehiscence (1) and biliary anastomotic leak (1). Conclusions: This study was planned to build on our previous gem-based preop chemoradiation program with an estimated accrual of 31 pts. However, interim analysis after accrual of 11 pts suggests that the rate of major postop complications was unforeseen and significant. The combined use of bevacizumab with radiation or gemcitabine (or both) may have contributed to poor wound healing. Optimal use of anti-VEGF therapy in the preop setting requires further refinement.
- 20 May 2008
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 26  (15_suppl) , 4630
Preoperative gemcitabine (gem) and bevacizumab (bev)-based chemoradiation for resectable pancreatic adenocarcinoma
4630 Background: Over 80% of pts who undergo potentially curative pancreaticoduodenectomy (PD) for pancreatic adenocarcinoma (PC) develop local or distant recurrence. Preoperative therapy maximizes the no. of pts who receive multimodality therapy and undergo a complete (R0) resection. Our phase I study using bev and capecitabine based chemoradiation for locally advanced PC was well tolerated. We hypothesized that gem and bev with RT in pts with resectable PC may allow more pts to undergo PD and improve the rate of R0 resections. Methods: Pts with biopsy proven, stage I/II adenoca of the pancreatic head or uncinate process received 6 wkly infusions of gem (400 mg/m2) and 3 infusions of bev (10 mg/kg, every 2 wks) with concomitant RT, 50.4 Gy at 1.8 Gy/fr. Pts were restaged 4–6 wks after the last dose of radiation. Those without disease progression and with good PS underwent surgery. Pts with adequate recuperation received bev (10mg/kg) every 2 weeks for 3 months starting ∼ 6 wks after surgery. Results: This study has enrolled 11 pts. Median age is 64 yrs; all pts had ECOG-PS 0–1. Median CA19–9 was 52. Of the 11 pts who finished chemoradiation, 10 underwent restaging and 1 pt died from cardiac arrest before restaging. At restaging, 1 pt. had metastatic disease, and 9 (90 %) went to surgery and underwent a successful (R0) PD. Pathologic PR rate (>50 % tumor kill) was 56 %. Preoperative grade 3–4 toxicities were infrequent and included stent related cholangitis (1), gastrointestinal toxicity (1), neutropenia (4), hypertension (1), and PE (1). Major postop complications occurred in 5 of the 9 pts (56%) who underwent PD including wound dehiscence (3) requiring reoperation, large ventral hernia related to fascial dehiscence (1) and biliary anastomotic leak (1). Conclusions: This study was planned to build on our previous gem-based preop chemoradiation program with an estimated accrual of 31 pts. However, interim analysis after accrual of 11 pts suggests that the rate of major postop complications was unforeseen and significant. The combined use of bevacizumab with radiation or gemcitabine (or both) may have contributed to poor wound healing. Optimal use of anti-VEGF therapy in the preop setting requires further refinement.
- 20 May 2008
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 26  (15) , 4501
Polymorphisms of genes involved in gemcitabine metabolism correlate with prognosis in patients receiving neoadjuvant therapy for pancreatic cancer
4501 Background: Genetic variations in gemcitabine transport and metabolism may affect the clinical response, toxicity, and prognosis of pancreatic cancer patients treated with gemcitabine. Methods: We evaluated 17 single nucleotide polymorphisms (SNPs) of 8 genes (CDA, dCK, RRM1, DCTD, hCNT1, hCNT2, hCNT3, and hENT1) involved in gemcitabine metabolism in a homogeneous population of 126 patients with resectable pancreatic cancer treated with neoadjuvant gemcitabine- based chemotherapy plus radiation therapy. Whole blood was collected from patients at the time of enrollment, and DNA was extracted from peripheral lymphocytes using a DNA isolation kit (Qiagen Valencia, CA). Polymorphisms were detected using the TaqMan genotyping assays provided by Applied Biosystems (Foster City, CA). Survival was determined from pathologic diagnosis to death or last follow-up. Kaplan-Meier plot, log-rank test, and Cox regression were used to compare survival of patients according to genotype. Results: Six of the 17 SNPs had a borderline-significant effect on OS (p CDA 111CC, CDA -76AA, RRM1 42GG, and DCTD -47CT (p hCNT1 -16AA/AG, hCNT2 -17CC, and hENT1 913CC (p = 0.006). The CDA C111T and dCK C-1205T genotypes were also significantly associated with toxicity (p = 0.05 and 0.03, respectively). The CDA 111CC and dCK -1205TT alleles that were associated with poorer survival actually conferred less toxicity. Conclusion. These observations suggest that polymorphic variants of gemcitabine metabolic genes play an important role in affecting the efficacy of gemcitabine treatment for patients with pancreatic cancer.
- 20 May 2008
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 26  (15) , 4501
Polymorphisms of genes involved in gemcitabine metabolism correlate with prognosis in patients receiving neoadjuvant therapy for pancreatic cancer
4501 Background: Genetic variations in gemcitabine transport and metabolism may affect the clinical response, toxicity, and prognosis of pancreatic cancer patients treated with gemcitabine. Methods: We evaluated 17 single nucleotide polymorphisms (SNPs) of 8 genes (CDA, dCK, RRM1, DCTD, hCNT1, hCNT2, hCNT3, and hENT1) involved in gemcitabine metabolism in a homogeneous population of 126 patients with resectable pancreatic cancer treated with neoadjuvant gemcitabine- based chemotherapy plus radiation therapy. Whole blood was collected from patients at the time of enrollment, and DNA was extracted from peripheral lymphocytes using a DNA isolation kit (Qiagen Valencia, CA). Polymorphisms were detected using the TaqMan genotyping assays provided by Applied Biosystems (Foster City, CA). Survival was determined from pathologic diagnosis to death or last follow-up. Kaplan-Meier plot, log-rank test, and Cox regression were used to compare survival of patients according to genotype. Results: Six of the 17 SNPs had a borderline-significant effect on OS (p CDA 111CC, CDA -76AA, RRM1 42GG, and DCTD -47CT (p hCNT1 -16AA/AG, hCNT2 -17CC, and hENT1 913CC (p = 0.006). The CDA C111T and dCK C-1205T genotypes were also significantly associated with toxicity (p = 0.05 and 0.03, respectively). The CDA 111CC and dCK -1205TT alleles that were associated with poorer survival actually conferred less toxicity. Conclusion. These observations suggest that polymorphic variants of gemcitabine metabolic genes play an important role in affecting the efficacy of gemcitabine treatment for patients with pancreatic cancer.
- 26 October 2007
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 15  (1) , 293-301
Failure to Recognize Multiple Endocrine Neoplasia 2B: More Common Than We Think?
Background Multiple endocrine neoplasia 2B (MEN2B) has a classic childhood phenotypic presentation characterized by mucosal neuromas and marfanoid habitus. However, the diagnosis of MEN2B is often...
- 26 October 2007
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 15  (1) , 293-301
Failure to Recognize Multiple Endocrine Neoplasia 2B: More Common Than We Think?
Background Multiple endocrine neoplasia 2B (MEN2B) has a classic childhood phenotypic presentation characterized by mucosal neuromas and marfanoid habitus. However, the diagnosis of MEN2B is often...
- 1 July 2007
- Published by Harborside Press, LLC in Journal of the National Comprehensive Cancer Network
- Vol. 5  (6) , 623-630
Role of Lymph Node Dissection in Primary Surgery for Thyroid Cancer
The preoperative evaluation of the clinically N0 neck and the operative management of cervical lymph nodes in patients with papillary and medullary thyroid cancer remains controversial. The appreciation that even patients with low-risk disease have a significant risk for recurrence has generated interest in a more comprehensive preoperative evaluation of the neck and has renewed debate on the extent of lymphadenectomy at the time of thyroidectomy. The authors recommend using preoperative ultrasound before thyroidectomy for all patients with thyroid cancer and before any subsequent surgeries for recurrent disease to identify the extent of lymph node metastases and thereby facilitate complete surgical removal of all gross disease in the neck. The optimal surgical procedure for removing cervical lymphadenopathy is compartment-oriented neck dissection based on the findings from preoperative ultrasound.
- 1 July 2007
- Published by Harborside Press, LLC in Journal of the National Comprehensive Cancer Network
- Vol. 5  (6) , 623-630
Role of Lymph Node Dissection in Primary Surgery for Thyroid Cancer
The preoperative evaluation of the clinically N0 neck and the operative management of cervical lymph nodes in patients with papillary and medullary thyroid cancer remains controversial. The appreciation that even patients with low-risk disease have a significant risk for recurrence has generated interest in a more comprehensive preoperative evaluation of the neck and has renewed debate on the extent of lymphadenectomy at the time of thyroidectomy. The authors recommend using preoperative ultrasound before thyroidectomy for all patients with thyroid cancer and before any subsequent surgeries for recurrent disease to identify the extent of lymph node metastases and thereby facilitate complete surgical removal of all gross disease in the neck. The optimal surgical procedure for removing cervical lymphadenopathy is compartment-oriented neck dissection based on the findings from preoperative ultrasound.
- 7 February 2007
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 14  (5) , 1525-1527
Surgical Management of Familial Hyperparathyroidism
- 7 February 2007
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 14  (5) , 1525-1527
Surgical Management of Familial Hyperparathyroidism